Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Osteocalcin does not influence acute or chronic inflammation in human vascular cells.

Millar SA, Zala I, Anderson SI, O'Sullivan SE.

J Cell Physiol. 2019 Sep 24. doi: 10.1002/jcp.29231. [Epub ahead of print]

PMID:
31549398
2.

Osteokines and the vasculature: a review of the in vitro effects of osteocalcin, fibroblast growth factor-23 and lipocalin-2.

Millar SA, Anderson SI, O'Sullivan SE.

PeerJ. 2019 Jul 24;7:e7139. doi: 10.7717/peerj.7139. eCollection 2019.

3.

Endocannabinoids and endocannabinoid-like compounds modulate hypoxia-induced permeability in CaCo-2 cells via CB1, TRPV1, and PPARα.

Karwad MA, Couch DG, Wright KL, Tufarelli C, Larvin M, Lund J, O'Sullivan SE.

Biochem Pharmacol. 2019 Oct;168:465-472. doi: 10.1016/j.bcp.2019.07.017. Epub 2019 Jul 17.

PMID:
31325449
4.

A Novel Transwell Blood Brain Barrier Model Using Primary Human Cells.

Stone NL, England TJ, O'Sullivan SE.

Front Cell Neurosci. 2019 Jun 6;13:230. doi: 10.3389/fncel.2019.00230. eCollection 2019.

5.

A systematic review of cannabidiol dosing in clinical populations.

Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan SE.

Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900. doi: 10.1111/bcp.14038. Epub 2019 Jul 19. Review.

6.

Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeability of the Human Gut In Vitro and In Vivo-A Randomized, Placebo-controlled, Double-blind Controlled Trial.

Couch DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE.

Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018. doi: 10.1093/ibd/izz017.

PMID:
31054246
7.

Human vascular cell responses to the circulating bone hormone osteocalcin.

Millar SA, Anderson SI, O'sullivan SE.

J Cell Physiol. 2019 Nov;234(11):21039-21048. doi: 10.1002/jcp.28707. Epub 2019 Apr 26.

8.

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans.

Millar SA, Stone NL, Yates AS, O'Sullivan SE.

Front Pharmacol. 2018 Nov 26;9:1365. doi: 10.3389/fphar.2018.01365. eCollection 2018.

9.

An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers.

Stone NL, Millar SA, Herrod PJJ, Barrett DA, Ortori CA, Mellon VA, O'Sullivan SE.

Front Behav Neurosci. 2018 Nov 26;12:269. doi: 10.3389/fnbeh.2018.00269. eCollection 2018.

10.

Genetic polymorphisms of the endocannabinoid system in obesity and diabetes.

Doris JM, Millar SA, Idris I, O'Sullivan SE.

Diabetes Obes Metab. 2019 Feb;21(2):382-387. doi: 10.1111/dom.13504. Epub 2018 Sep 16.

PMID:
30129173
11.

The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.

Couch DG, Maudslay H, Doleman B, Lund JN, O'Sullivan SE.

Inflamm Bowel Dis. 2018 Mar 19;24(4):680-697. doi: 10.1093/ibd/izy014.

PMID:
29562280
12.

A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ⁸-Tetrahydrocannabinol.

Sultan SR, Millar SA, O'Sullivan SE, England TJ.

Pharmaceuticals (Basel). 2018 Jan 31;11(1). pii: E13. doi: 10.3390/ph11010013. Review.

13.

Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon.

Couch DG, Tasker C, Theophilidou E, Lund JN, O'Sullivan SE.

Clin Sci (Lond). 2017 Oct 25;131(21):2611-2626. doi: 10.1042/CS20171288. Print 2017 Nov 1.

PMID:
28954820
14.

The Role of Nuclear Hormone Receptors in Cannabinoid Function.

Pistis M, O'Sullivan SE.

Adv Pharmacol. 2017;80:291-328. doi: 10.1016/bs.apha.2017.03.008. Epub 2017 May 25. Review.

PMID:
28826538
15.

Osteocalcin, Vascular Calcification, and Atherosclerosis: A Systematic Review and Meta-analysis.

Millar SA, Patel H, Anderson SI, England TJ, O'Sullivan SE.

Front Endocrinol (Lausanne). 2017 Jul 31;8:183. doi: 10.3389/fendo.2017.00183. eCollection 2017.

16.

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Jadoon KA, Tan GD, O'Sullivan SE.

JCI Insight. 2017 Jun 15;2(12). pii: 93760. doi: 10.1172/jci.insight.93760. eCollection 2017 Jun 15.

17.

In Vivo Cannabidiol Treatment Improves Endothelium-Dependent Vasorelaxation in Mesenteric Arteries of Zucker Diabetic Fatty Rats.

Wheal AJ, Jadoon K, Randall MD, O'Sullivan SE.

Front Pharmacol. 2017 May 18;8:248. doi: 10.3389/fphar.2017.00248. eCollection 2017.

18.

The role of CB1 in intestinal permeability and inflammation.

Karwad MA, Couch DG, Theophilidou E, Sarmad S, Barrett DA, Larvin M, Wright KL, Lund JN, O'Sullivan SE.

FASEB J. 2017 Aug;31(8):3267-3277. doi: 10.1096/fj.201601346R. Epub 2017 Apr 12.

PMID:
28404744
19.

A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol.

Sultan SR, Millar SA, England TJ, O'Sullivan SE.

Front Pharmacol. 2017 Feb 24;8:81. doi: 10.3389/fphar.2017.00081. eCollection 2017.

20.

The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries.

Stanley CP, Hind WH, Tufarelli C, O'Sullivan SE.

Pharmacol Res. 2016 Nov;113(Pt A):356-363. doi: 10.1016/j.phrs.2016.08.028. Epub 2016 Sep 12.

21.

Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα.

Karwad MA, Macpherson T, Wang B, Theophilidou E, Sarmad S, Barrett DA, Larvin M, Wright KL, Lund JN, O'Sullivan SE.

FASEB J. 2017 Feb;31(2):469-481. doi: 10.1096/fj.201500132. Epub 2016 Sep 13.

PMID:
27623929
22.

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD.

Diabetes Care. 2016 Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29.

PMID:
27573936
23.

An update on PPAR activation by cannabinoids.

O'Sullivan SE.

Br J Pharmacol. 2016 Jun;173(12):1899-910. doi: 10.1111/bph.13497. Epub 2016 May 19. Review.

24.

The endogenous cannabinoid anandamide increases human airway epithelial cell permeability through an arachidonic acid metabolite.

Shang VC, O'Sullivan SE, Kendall DA, Roberts RE.

Pharmacol Res. 2016 Mar;105:152-63. doi: 10.1016/j.phrs.2016.01.023. Epub 2016 Jan 22.

PMID:
26808080
25.

Remote effects of acute kidney injury in a porcine model.

Gardner DS, De Brot S, Dunford LJ, Grau-Roma L, Welham SJ, Fallman R, O'Sullivan SE, Oh W, Devonald MA.

Am J Physiol Renal Physiol. 2016 Feb 15;310(4):F259-71. doi: 10.1152/ajprenal.00389.2015. Epub 2015 Nov 25.

26.

Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors.

Hind WH, England TJ, O'Sullivan SE.

Br J Pharmacol. 2016 Mar;173(5):815-25. doi: 10.1111/bph.13368. Epub 2016 Feb 3.

27.

The Effects of the Endocannabinoids Anandamide and 2-Arachidonoylglycerol on Human Osteoblast Proliferation and Differentiation.

Smith M, Wilson R, O'Brien S, Tufarelli C, Anderson SI, O'Sullivan SE.

PLoS One. 2015 Sep 28;10(9):e0136546. doi: 10.1371/journal.pone.0136546. eCollection 2015.

28.

Endocannabinoids and the Cardiovascular System in Health and Disease.

O'Sullivan SE.

Handb Exp Pharmacol. 2015;231:393-422. doi: 10.1007/978-3-319-20825-1_14. Review.

PMID:
26408169
29.

Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation.

Stanley CP, Hind WH, Tufarelli C, O'Sullivan SE.

Cardiovasc Res. 2015 Sep 1;107(4):568-78. doi: 10.1093/cvr/cvv179. Epub 2015 Jun 19.

30.

Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis.

Mallipedhi A, Prior SL, Dunseath G, Bracken RM, Barry J, Caplin S, Eyre N, Morgan J, Baxter JN, O'Sullivan SE, Sarmad S, Barrett DA, Bain SC, Luzio SD, Stephens JW.

J Diabetes Res. 2015;2015:680867. doi: 10.1155/2015/680867. Epub 2015 Mar 22.

31.

Endocannabinoids modulate human blood-brain barrier permeability in vitro.

Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE.

Br J Pharmacol. 2015 Jun;172(12):3015-27. doi: 10.1111/bph.13106. Epub 2015 Apr 10.

32.

Defining uremic arterial functional abnormalities in patients recently started on haemodialysis: combined in vivo and ex vivo assessment.

Abushufa AM, Eldehni MT, Odudu A, Evans PD, O'Sullivan SE, McIntyre CW.

PLoS One. 2014 Dec 29;9(12):e113462. doi: 10.1371/journal.pone.0113462. eCollection 2014.

33.

Cannabinoids in experimental stroke: a systematic review and meta-analysis.

England TJ, Hind WH, Rasid NA, O'Sullivan SE.

J Cereb Blood Flow Metab. 2015 Mar;35(3):348-58. doi: 10.1038/jcbfm.2014.218. Epub 2014 Dec 10. Review.

34.

Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation.

Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O'Sullivan SE.

J Pharmacol Exp Ther. 2014 Nov;351(2):457-66. doi: 10.1124/jpet.114.217125. Epub 2014 Sep 11.

PMID:
25212218
35.

The effects of obesity, diabetes and metabolic syndrome on the hydrolytic enzymes of the endocannabinoid system in animal and human adipocytes.

Cable JC, Tan GD, Alexander SP, O'Sullivan SE.

Lipids Health Dis. 2014 Mar 4;13:43. doi: 10.1186/1476-511X-13-43.

36.

Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries.

Stanley CP, O'Sullivan SE.

Pharmacol Res. 2014 Mar;81:74-82. doi: 10.1016/j.phrs.2014.02.001. Epub 2014 Feb 16.

37.

Vascular targets for cannabinoids: animal and human studies.

Stanley C, O'Sullivan SE.

Br J Pharmacol. 2014 Mar;171(6):1361-78. doi: 10.1111/bph.12560. Review.

38.

Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes.

Stanley CP, Wheal AJ, Randall MD, O'Sullivan SE.

Eur J Pharmacol. 2013 Nov 15;720(1-3):376-82. doi: 10.1016/j.ejphar.2013.10.002. Epub 2013 Oct 8.

PMID:
24120371
39.

Is the cardiovascular system a therapeutic target for cannabidiol?

Stanley CP, Hind WH, O'Sullivan SE.

Br J Clin Pharmacol. 2013 Feb;75(2):313-22. doi: 10.1111/j.1365-2125.2012.04351.x. Review.

40.

The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans.

Cable JC, Tan GD, Alexander SP, O'Sullivan SE.

Lipids Health Dis. 2011 Aug 4;10:129. doi: 10.1186/1476-511X-10-129.

41.

Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.

Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE.

Br J Pharmacol. 2012 Apr;165(8):2598-610. doi: 10.1111/j.1476-5381.2011.01589.x.

42.

Endocannabinoids and the cardiovascular response to stress.

O'Sullivan SE, Kendall PJ, Kendall DA.

J Psychopharmacol. 2012 Jan;26(1):71-82. doi: 10.1177/0269881111408457. Epub 2011 Jun 27. Review.

PMID:
21708837
43.

Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability.

Alhamoruni A, Lee AC, Wright KL, Larvin M, O'Sullivan SE.

J Pharmacol Exp Ther. 2010 Oct;335(1):92-102. doi: 10.1124/jpet.110.168237. Epub 2010 Jun 30.

PMID:
20592049
44.

Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.

O'Sullivan SE, Kendall DA.

Immunobiology. 2010 Aug;215(8):611-6. doi: 10.1016/j.imbio.2009.09.007. Epub 2009 Oct 14. Review.

PMID:
19833407
45.

Time-dependent vascular effects of Endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARγ).

O'Sullivan SE, Kendall DA, Randall MD.

PPAR Res. 2009;2009:425289. doi: 10.1155/2009/425289. Epub 2009 Apr 29.

46.

Time-dependent vascular actions of cannabidiol in the rat aorta.

O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA.

Eur J Pharmacol. 2009 Jun 10;612(1-3):61-8. doi: 10.1016/j.ejphar.2009.03.010. Epub 2009 Mar 11.

PMID:
19285060
47.

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

O'Sullivan SE.

Br J Pharmacol. 2007 Nov;152(5):576-82. Epub 2007 Aug 20. Review.

48.

Rimonabant in obese patients with type 2 diabetes.

Randall MD, Kendall DA, Bennett AJ, O'Sullivan SE.

Lancet. 2007 Feb 17;369(9561):555. No abstract available.

PMID:
17307094
49.

The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase.

O'Sullivan SE, Randall MD, Gardiner SM.

J Pharmacol Exp Ther. 2007 May;321(2):663-72. Epub 2007 Feb 6.

PMID:
17284670
50.

What is the significance of vascular hydrogen sulphide (H2S)?

O'Sullivan SE.

Br J Pharmacol. 2006 Nov;149(6):609-10. Epub 2006 Oct 3.

Supplemental Content

Loading ...
Support Center